<DOC>
	<DOCNO>NCT02429024</DOCNO>
	<brief_summary>Assessment SMS Smartphone Interventions OneTouch Reveal® Experiences patient Type I Type II diabetes .</brief_summary>
	<brief_title>Assessment SMS Smartphone Interventions OneTouch Reveal® Experiences</brief_title>
	<detailed_description>The primary objective demonstrate improve A1c study subject type 1 type 2 diabetes use OneTouch Verio® Flex BGM OneTouch Reveal® Mobile APP system period 24 week , compare subject use OneTouch Verio® Flex BGM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Male female , least 18 year old ( legal age consent jurisdiction study take place ) 70 year old , inclusive ; Has A1c ≥7.5 ≤ 11.0 % screening visit ; It medically appropriate opinion investigator Subject attempt achieve level glycemic control line ADA guideline glyceamic recommendation ( &lt; 7.0 % A1c , preprandial capillary glucose 3.97.2mmol/l peak postprandial glucose &lt; 10.0mmol/l ) ; Diagnosed T2DM T1DM ≥ 3 month prior screen ; Currently perform SMBG home diabetes management decision willing test SMBG ≥ 1 per day subject Type 2 diabetes AHA and/or noninsulin injectable ( e.g . GLP1 ) , ≥ 2 per day basal insulin premixed insulin ; test ≥ 3 time per day subject Type 2 diabetes MDI subject Type 1 diabetes . Willing send receive SMS message use sponsor smartphone 2 weekly interval throughout study ( note : inclusion applies subject regardless whether subsequently randomize control intervention ) Is locate area send receive SMS message access phone signal use 3G network require On stable dose antihyperglycemic agent ( AHA ) , include oral hypoglycemics ( OAs ) , noninsulin injectables ( e.g . GLP1 ) insulin therapy ≥ 2 month prior screen ; ( Note : definition stable include subject routinely selfadjust insulin base 'in moment ' SMBG value . Stable include actual diabetes therapy change ( e.g . new oral medication , initiate insulin change insulin regimen , insulin carb ratio change basal bolus insulin progression ) Antihyperglycemic agent ( AHA ) ( OAs GLP1s ) must consistent UK label subject 's insulin type ; Willingness use CGM device study period ; Willingness notify study staff become pregnant study ; Willingness practice appropriate form birth control study child bear potential ; Able communicate ( speak , read write ) English , able understand sign require study document ; Have sign inform consent ( regional equivalent ) document indicate understand purpose procedure study ; Is unlikely compliant currently prescribe diabetes regimen , opinion study staff ; Currently pregnant plan pregnancy within duration study breast feeding ; Has unstable ( rapidly progress ) retinopathy opinion study staff may require surgical treatment ( include laser photocoagulation ) study Is currently receive treatment past 3 month Systemic corticosteroid antipsychotic drug prescription cannabinoid Is currently psychiatrically unstable opinion study staff Has know clinically significant and/or unstable medical condition , opinion study staff , include : Cardiovascular disease , Hematological disease , Hepatic disease , Gastrointestinal disease , Endocrine/metabolic disorder Neurologic disease Malignant neoplasm require treatment past 5 year , basal cell/squamous cell carcinoma skin History major surgery within 6 month Has condition opinion study staff would complicate compromise study , well Subject Subject employee investigator clinical site ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>A1c</keyword>
</DOC>